1 unchanged sentence
Rule 10b5-1 Trading Arrangements
−Removed: During the three months ended March 31, 2026, each of the Company’s directors and executive officers adopted a “Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
−Removed: Each of the arrangements was entered into on or about January 28, 2026 and provides for the sale by the Company's broker of shares of the Company's common stock issued upon the vesting of restricted stock awards (“RSAs”) and restricted stock units (the “RSUs”), granted under the Company's 2021 Equity Incentive Plan, solely to satisfy tax withholding obligations associated with such vesting.
−Removed: The aggregate number of shares to be sold under each arrangement is not presently determinable, as it depends on the applicable tax withholding rate at the time of each vesting event.
−Removed: Each arrangement will terminate upon the final vesting of the RSAs and RSUs covered thereby, which is scheduled to occur on or before January 8, 2028.
−Removed: No director or officer adopted, modified, or terminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended March 31, 2026.
+Added: During the three months ended June 30, 2026, no director or officer adopted , modified , or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) or a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
Exhibits, Financial Statement Schedules.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
−Removed: Amendment to the Third Amended and Restated Certificate of Incorporation, effective January 28, 2026
Revelation Biosciences, Inc.
2026 Equity Inducement Plan
−Removed: Non-Plan Employee Inducement Restricted Stock Unit Award Agreement between the Registrant and Kyle Chaykowski dated January 8, 2026
+Added: Form of Restricted Stock Unit Grant Notice under 2026 Equity Inducement Plan
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a_14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
15 unchanged sentences
REVELATION BIOSCIENCES, INC.
+Added: August 6, 2026
/s/ James Rolke
1 unchanged sentence
(principal executive officer)
+Added: August 6, 2026
/s/ Chester S.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.